ezetimibe
Prescribing Info
Prescribing information explains how to adjust treatment of certain medications based on a person’s genetic information, and includes information from clinical guideline annotations, drug label annotations and Rx study annotations.
Drug Label Annotations with Genotype-Based Prescribing Information
These are PharmGKB Drug Label Annotations with a "Prescribing" section. Information is added to this section if an annotation is tagged with "Dosing Info" or "Alternative Drug", or if any other guidance is given on the label for patients with a particular genotype or metabolizer phenotype. Examples of such guidance are (1) if a dosing change or alternate drug is "recommended", "suggested" or "should be considered", (2) if a drug "should be used with caution", or (3) if clinicians should "monitor" these patients for adverse events/reactions.
Annotation of Swissmedic Label for ezetimibe / rosuvastatin
Dosage: Specific types of genetic polymorphisms are known that may lead to an increase in rosuvastatin exposure (see "Pharmacokinetics"). In patients in whom such a polymorphism is known, a reduction in the dosage of ezetimib-rosuvastatin mepha is recommended.
Continue reading Annotation of Swissmedic Label for ezetimibe / rosuvastatin
Annotation of Swissmedic Label for ezetimibe / simvastatin
Where available, genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype. However, the absence of this gene in genotyping does not exclude the possibility of myopathy.
Continue reading Annotation of Swissmedic Label for ezetimibe / simvastatin